Overall survival in POLO study of olaparib maintenance for metastatic germline BRCA-mutated metastatic pancreatic cancer

The multinational phase 3 POLO trial included patients with metastatic pancreatic adenocarcinoma and a germline BRCA mutation without progression after at least 16 weeks of first-line platinum-based chemotherapy. The patients were randomized to olaparib or placebo maintenance therapy. There was no statistically OS benefit for olaparib relative to placebo (median 19.0 versus 19.2 months; p=0.3487). However, the OS-curves separated after approximately 24 months, and the estimated 3-year OS was 33.9% versus 17.8%. Median time to first subsequent cancer therapy or death, time to second subsequent therapy or death, and time to discontinuation or death significantly favored olaparib. Olaparib was well tolerated.